How many drugs treat Atrophic vulva?

Drug Landscape tracks 6 marketed treatments for Atrophic vulva (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Atrophic vulva?

Most recent: Estring — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/atrophic-vulva.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Atrophic vulva — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Atrophic vulva (disease) competitive landscape: 6 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

6 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Atrophic vulva, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Slynd	DROSPIRENONE	Exeltis Usa Inc	Progestin	Mineralocorticoid receptor	2019-01-01
Osphena	OSPEMIFENE	Duchesnay	Estrogen Agonist/Antagonist [EPC]	Estrogen receptor beta	2013-01-01
Estrace	ESTRADIOL	Pfizer	Estrogen	Estrogen receptor	1975-01-01
Micronor	norethisterone	Johnson & Johnson	Progestin	GnRH receptors	1962-01-01
Synestrol	DIENESTROL	Johnson & Johnson	dienestrol	Estrogen receptor	1947-01-01
Ortho-Novum 10/11-21	Ethinylestradiol	Merck & Co.	Estrogen	Estrogen receptor	1943-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-05-11 — Estring · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Johnson & Johnson · 2 drugs in Atrophic vulva
Duchesnay · 1 drug in Atrophic vulva
Exeltis Usa Inc · 1 drug in Atrophic vulva
Merck & Co. · 1 drug in Atrophic vulva
Pfizer · 1 drug in Atrophic vulva
Pfizer Inc. · 1 drug in Atrophic vulva

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Atrophic vulva:

Cite this brief

Drug Landscape (2026). Atrophic vulva — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/atrophic-vulva. Accessed 2026-06-10.

Atrophic vulva full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing